The success of modern targeted cancer therapies is fundamentally dependent on the use of Biomarker-driven therapies . This approach involves using a biological marker, or biomarker, to identify patients who are most likely to benefit from a specific treatment. By linking the right drug to the right patient, biomarker-driven therapies maximize efficacy, minimize unnecessary toxicity, and optimize healthcare resources. The global targeted cancer therapies market, valued at USD 335.42 billion in 2025 and projected to grow to USD 912.18 billion by 2035, is a testament to the power and importance of this strategy.

Biomarker-driven therapies are a cornerstone of precision oncology. They are based on the principle that cancer is a heterogeneous disease, and that different patients' tumors have different molecular drivers. By identifying these drivers—such as specific genetic mutations or protein overexpression—clinicians can select therapies that are specifically designed to attack them. For example, the presence of an EGFR mutation in non-small cell lung cancer is a biomarker that predicts a response to EGFR tyrosine kinase inhibitors. The use of these biomarkers is not just about predicting response; they can also be used to monitor for resistance, allowing for timely adjustments to therapy.

The Development and Use of Biomarkers

The development of biomarker-driven therapies is a collaborative effort between diagnostic companies and drug developers. A companion diagnostic is a test that is required to select patients for a specific therapy. These tests must be validated to ensure they are accurate and reliable. The use of biomarkers has become increasingly sophisticated, with the development of multi-gene panels and next-generation sequencing allowing for the simultaneous detection of multiple biomarkers. The integration of liquid biopsy technologies, which analyze circulating tumor DNA (ctDNA) from a blood sample, is expanding the applications of biomarkers for monitoring disease and detecting resistance. The continuous discovery of new biomarkers is a key driver of growth in the targeted therapy market.

Future of Biomarker-Guided Therapy

The future of biomarker-driven therapies is focused on expanding the number of actionable biomarkers, developing more comprehensive testing panels, and integrating biomarkers into clinical decision-making. The use of artificial intelligence is accelerating the discovery of new biomarkers. The development of "theranostics," which combines diagnostics and therapeutics, is an emerging field where biomarkers are used to guide treatment with radiolabeled agents. The focus on biomarkers is also expanding into immuno-oncology, with the development of biomarkers like PD-L1 expression to predict response to checkpoint inhibitors. As the field of precision oncology continues to advance, the role of Biomarker-driven therapies in guiding cancer treatment will only become more central.